Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Abbott Upgrading Texas Rx Plant Following GMP Warning Letter

  • News

Executive Summary

Abbott is accelerating enhancement of the monitoring system validation program for manufacturing at its Austin, Tex. facility following receipt of an FDA warning letter

You may also be interested in...



Abbott Hospital Products Spin-Off Will Free Up $500 Mil. For Rx Spending

Abbott's planned spin-off of a new hospital products company will free up approximately $500 mil. to invest in R&D and promotional support for Humira

Abbott Hospital Products Spin-Off Will Free Up $500 Mil. For Rx Spending

Abbott's planned spin-off of a new hospital products company will free up approximately $500 mil. to invest in R&D and promotional support for Humira

FDA Reinspecting Abbott Depakote ER Backup Facility After Warning Letter

FDA is reinspecting Abbott's Abbott Park, Ill. manufacturing facility as a follow-up to a warning letter citing violations of good manufacturing practices

Table

View full table

Tags:
Latest Headlines

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

See All
UsernamePublicRestriction

Register

PS040706

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By